Tailwinds' Take: Looking forward to seeing more data on the BVA-100. The medical community is just waking up to the incredible savings in mortality associated with proper blood volume management. NEW YORK, Feb. 13, 2019 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE...

Daxor Emerges

Accurate blood volume monitoring can save lives and reduce medical costs The BVA 100 is the only approved product on the market Hospitals are incentivized to adopt the product The market opportunity is large Daxor emerges Similar to how...
NEW YORK, Jan. 23, 2019 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), an innovative medical instrumentation and biotechnology company focused on blood volume measurement today announces the appointment of Guido Manzo as Vice President of Sales. "Guido joins Daxor with...
NEW YORK, Jan. 10, 2019 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announces that Aspirus Wausau Hospital in Wausau Wisconsin has acquired a BVA-100...
NEW YORK, Nov. 13, 2018 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announces new data from Duke University Medical Center that was presented Saturday,...
DFC Advisory Services LLC (dba Tailwinds Research) is a registered investment adviser. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Past performance is not indicative of future performance.